Notations From the Grid (Weekly Edition): Out & About In Our World.....

 

As March Dawns, We present some thoughts  on happenings in our World as we look forward to exploring thoughts and ideas courtesy Peter Diamandis and the Information: 

What if a microscopic robot could treat diseases from within your body? That’s the vision of Bionaut Labs, an Israel-based startup that represents the future of converging technologies that impact healthcare. (Full disclosure: my venture fund BOLD Capital is an investor in Bionaut Labs.) Many of the issues we face in medicine today are local in nature. Take brain, lung, or ovarian cancer. Unfortunately, we treat these local cancer issues with solutions like chemotherapy that affect the entire body. These broad, systemic solutions tend to be inaccurate, inefficient, and prone to significant side effects. These are some of the reasons why drug design is so astronomically expensive. The unintended side effects of drugs is also why the majority of treatment candidates never make it out of the lab.  But Bionaut Labs seeks to change this.  The company’s remote-controlled microbots travel through the body with precision delivering therapeutic payloads—in a minimally invasive manner.  In today’s blog, I’m going to give you an overview of Bionaut Labs, how their technology works, and what this means for the future of healthcare.  Let’s dive in! WHAT IS BIONAUT LABS? Bionaut Labs first seeks to revolutionize the treatment of central nervous system (CNS) disorders using robots that are smaller than a grain of rice.  These microbots, called Bionauts, are remotely controlled by directed magnetic forces to deliver biologics and small molecule therapeutics with unprecedented precision. So, where did the inspiration for creating Bionauts come from? CEO Michael Shpigelmacher and Co-founder Aviad Maizels started the company after Aviad’s mother, a senior drug development executive, repeatedly highlighted the unmet need for accurate localized drug delivery.  They realized that too many treatments are still systemic in nature and rely on statistical probabilities instead of actually reaching the target tissue. Bionaut Labs was founded in 2016 to solve this very issue. The company’s tiny robots are currently designed to deliver therapeutics, but future generations of the devices could provide electrical stimulation, thermal ablation, or radioactive plaque to treat other diseases.  Even more, the Bionauts will contain diagnostic tools to evaluate signals and adjust therapy accordingly in an ongoing closed-loop cycle.  HOW EXACTLY DO BIONAUTS WORK? The magnetic Bionauts, measuring less than a millimeter in diameter, have precise geometric features on the micrometer scale, thanks to 3D photolithography manufacturing.  They are injected intrathecally into the lumbar spine (the same procedure as an epidural), or behind the skull and are then guided by magnetic controllers to the target site. The magnetic energy required is less than 10% of that used in MRIs and is much cheaper to generate. The first generation Bionauts will have automated control, though doctors will still oversee the microbots as they travel through the patient's body. Eventually, as doctors grow more comfortable with the technology, they will allow the Bionauts to operate more independently. And Bionauts move at a reasonable speed. Moving from the lumbar spine to a specific region of the brain takes a Bionaut just 5 to 10 minutes. Once inside the brain tissue, located adjacent to the tumor, the Bionauts are magnetically triggered to release their payload. Their accuracy is on par with surgeons, whose standard deviation falls in the single millimeter range.  Compared to other drug delivery techniques, such as syringes or catheters, Bionauts offer much more control and safety by limiting off-target effects.  The Bionauts then exit the body through the same portal from which they entered, leaving minimal trace.  In the future, some biocompatible materials, like iron, could even allow Bionauts to decompose naturally in the body rather than being removed surgically–further streamlining the procedure. With human trials fast approaching, we’ll soon have a better sense of all the potential applications of the Bionauts. IMPLICATIONS FOR THE FUTURE OF HEALTHCARE So, what does all of this mean for the future for healthcare? The Bionaut technology’s earliest indications are for payload-focused treatments in Glioma and Huntington’s Disease, both rare diseases with high unmet need. Preclinical animal phase testing in pigs and sheep is currently underway, and the company plans to apply for orphan drug designation for Brain Stem Glioma later this year.  Bionaut Labs will then begin FDA-regulated GLP (Good Laboratory Practice) and CGMP (Current Good Manufacturing Practice) work in 2022, ahead of human clinical trials in 2023. But simply delivering therapeutics and treating orphan diseases like Huntington's Disease is just the beginning for Bionaut’s microbots.  In the years to come, resident Bionauts could remain in the body, continuously monitoring tissues to detect diseases before symptoms present. For example, early diagnosis and treatment of Alzheimer’s Disease improves disease outcomes drastically. Bionauts could provide ongoing surveillance to stave off the progression of this and many other diseases. It’s incredible to think that all of this potential exists in a vessel smaller than a grain of rice. And as the Bionauts continue to shrink in size, their future applications will grow. Take ophthalmology, where minimally invasive delivery to the eye could precisely treat macular degeneration and diabetic retinopathy.  FINAL THOUGHTS Technologies such as Bionauts and the many other medical robots entering the healthcare arena are resulting from the extraordinary convergence of exponential technologies. The combination of computation, AI, sensors, networks, 3D printing, VR and AR is transforming how we find and treat disease. Healthcare is one industry where we will continue to see some of the most extraordinary and impactful demonstrations of converging exponentials.  If you’re an ambitious entrepreneur interested in healthcare, there’s never been a better time to get involved.

Tech Briefing February 22, 2021 Greetings! All those worries about the impact of cord-cutting seem to be in the rear-view mirror. The latest group of stocks to take flight are the traditional entertainment companies, proving that for media investors, it doesn’t matter how troubled your business is as long as you have a streaming story to tell. Take TV firm Discovery, whose stock rose 9% on Monday after the company reported its net income fell nearly in half on revenue that was flat. That brings its price appreciation since late October to 180%, echoed by similar rallies in the stocks of ViacomCBS and Disney. Investors of course look ahead, and their focus lately has been on new streaming services, such as Discovery+ (the plus symbol being de rigueur nowadays for new streaming names). That new service has added close to seven million subscribers globally since it launched seven weeks ago, Discovery executives indicated today, of which more than half are in the U.S. As impressive as that is, it doesn’t justify the current investor euphoria. Think of it this way: To generate as much revenue as Discovery’s U.S. TV networks, Discovery+ would need close to 65 million streaming subscribers in the U.S., back-of-the-envelope math suggests. Yet Netflix, after more than a decade operating its streaming service, barely has that many here. And the market is crowded: Discovery is competing with Netflix, Amazon Prime, Disney+, HBO Max and countless smaller services. And as the average household isn’t likely to sign up for more than four or five streaming services, not all can succeed. The bottom line: Streaming can’t replace what entertainment companies are losing from the old cable TV business. Yet the stocks imply the opposite. Something is wrong with this TV picture.—Martin Peers